Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Onxeo SA
Pierre Fabre Launches Pivotal Trial Of Pioneering Prenatal Therapy
The first boy suffering from X-linked hypohidrotic ectodermal dysplasia has been injected with a protein replacement therapy developed by the French firm and the Esperare Foundation while inside his mother's womb.
Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip
Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.
Deals Shaping The Medical Industry, October 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.
Deal Watch: Are Ultragenyx, REGENXBIO In A Bidding War For Dimension?
ProQR spinout Amylon gets started by licensing four central nervous system disorder candidates from its parent, while start-up Eyevance gets US rights to Nicox’s Zerviate.
- Other Names / Subsidiaries
- Apoxis SA
- BioAlliance Pharma
- Onxeo S.A.
- Onxeo US
- TopoTarget A/S
- DNA Therapeutics SA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.